Clinic
UPMC Presbyterian Shadyside
UPMC Presbyterian Shadyside was paid $125.54M by Medicaid between Jan 2018 and Dec 2024, across 579 billing codes. Its largest line is H2011, Crisis intervention service, per 15 minutes — 11% of everything it billed.
33Billing provider infoUPMC PRESBYTERIAN SHADYSIDE
PITTSBURGH, PA 15213
PITTSBURGH, PA 15213
33aNPI1821007881assigned 08/07/2006
33bProvider typeClinic/Center
28Total paid$125.54M
24GClaims1,693,653
24DCodes billed579
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#2 of 176
Median peer was paid$441K
This provider vs. median285×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,968 | $227K | |
| 2019 | 4,487 | $130K | |
| 2020 | 180,413 | $10.98M | |
| 2021 | 653,235 | $35.49M | |
| 2022 | 303,895 | $24.55M | |
| 2023 | 303,829 | $28.12M | |
| 2024incomplete | 244,826 | $26.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H2011 | Crisis intervention service, per 15 minutes | 11% | 51,356 | 30,846 | $14.36M |
| T1017 | Case management, billed per 15 minutesTargeted case management, each 15 minutes | 11% | 121,901 | 41,585 | $14.02M |
| H0039 | Assertive community treatment, face-to-face, per 15 minutes | 8.4% | 77,931 | 8,297 | $10.56M |
| S9485 | Crisis intervention mental health services, per diem | 6.0% | 12,804 | 2,400 | $7.51M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 5.9% | 85,097 | 46,274 | $7.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.3% | 43,738 | 41,152 | $6.71M |
| 90792 | Psychiatric diagnostic evaluation with medical services | 5.3% | 17,179 | 15,387 | $6.64M |
| H0037 | Community psychiatric supportive treatment program, per diem | 4.5% | 18,073 | 634 | $5.70M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 3.5% | 13,107 | 2,039 | $4.42M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 3.1% | 24,588 | 19,060 | $3.90M |
| H2021 | Community-based wrap-around services, per 15 minutes | 3.0% | 28,370 | 3,933 | $3.80M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.9% | 52,311 | 10,349 | $3.70M |
567 more codes
| G0378 | Hospital observation service, per hour | 2.8% | 12,039 | $3.53M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 2.3% | 18,194 | $2.94M |
| 99285 | Emergency room visit (most serious) | 1.8% | 13,212 | $2.29M |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 1.8% | 74,251 | $2.23M |
| H0046 | Mental health services, not otherwise specified | 1.5% | 14,592 | $1.88M |
| 97153 | Applied behavior analysis (autism therapy), per 15 minutes | 1.2% | 10,854 | $1.49M |
| 99283 | Emergency room visit (moderate) | 1.1% | 14,103 | $1.35M |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 1.1% | 14,278 | $1.33M |
| 97151 | 1.0% | 4,769 | $1.30M | |
| 90832 | Psychotherapy session, about 30 minutes | 1.0% | 32,814 | $1.27M |
| 90870 | <1% | 3,036 | $1.07M | |
| H0034 | Medication training and support, per 15 minutes | <1% | 14,053 | $1.03M |
| 97155 | Adaptive behavior treatment with protocol modification, administered by physician, each 15 minutes | <1% | 4,334 | $931K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15,226 | $921K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 5,069 | $834K |
| H0036 | Community psychiatric support and treatment, per 15 minutes | <1% | 12,228 | $727K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,339 | $547K |
| T1016 | Case management, each 15 minutes | <1% | 2,563 | $494K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,780 | $435K |
| H2015 | Community support for mental illness or disability, per 15 minutes | <1% | 2,209 | $430K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,586 | $322K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,436 | $282K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 337 | $278K |
| Q3014 | Telehealth originating site facility fee | <1% | 16,555 | $252K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,174 | $227K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,091 | $209K |
| 80053 | Comprehensive metabolic panel | <1% | 24,363 | $207K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 5,793 | $197K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,253 | $191K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 2,302 | $180K |
| H2019 | Therapeutic behavioral services, billed per 15 minutes | <1% | 10,324 | $170K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29,069 | $159K |
| 87536 | <1% | 1,579 | $158K | |
| 77386 | <1% | 603 | $151K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 609 | $147K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,062 | $144K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | <1% | 2,956 | $140K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,543 | $137K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,633 | $137K |
| J3490 | Unclassified drugs | <1% | 14,432 | $133K |
| 72141 | <1% | 649 | $130K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,609 | $128K |
| 74183 | <1% | 344 | $126K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 878 | $121K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,979 | $115K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,024 | $103K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,774 | $93K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,814 | $85K |
| 77301 | <1% | 182 | $82K | |
| 64415 | <1% | 193 | $80K | |
| 71250 | <1% | 1,434 | $74K | |
| 84484 | <1% | 11,902 | $73K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,326 | $73K |
| 73221 | <1% | 308 | $71K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 634 | $70K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,330 | $70K |
| 99241 | <1% | 705 | $70K | |
| H0030 | Behavioral health hotline service | <1% | 23,600 | $70K |
| 83735 | <1% | 15,481 | $69K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,348 | $67K |
| 70496 | <1% | 498 | $64K | |
| 97156 | <1% | 545 | $64K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 363 | $62K |
| 85610 | <1% | 13,615 | $60K | |
| 93975 | <1% | 735 | $59K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,088 | $58K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 405 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,160 | $56K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 243 | $54K |
| 86832 | <1% | 582 | $54K | |
| 74178 | <1% | 308 | $52K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 654 | $52K |
| 70498 | <1% | 431 | $52K | |
| 70544 | <1% | 299 | $51K | |
| 43248 | <1% | 130 | $49K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 22,289 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,763 | $47K |
| 74174 | <1% | 208 | $46K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,795 | $44K |
| 76536 | <1% | 1,058 | $43K | |
| 72197 | <1% | 122 | $41K | |
| 80050 | General health panel | <1% | 1,061 | $41K |
| 62323 | <1% | 586 | $40K | |
| 70491 | <1% | 709 | $40K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,663 | $40K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 522 | $39K |
| 80061 | Lipid panel | <1% | 3,965 | $39K |
| 10005 | <1% | 115 | $38K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 40 | $38K |
| 75561 | <1% | 109 | $34K | |
| 72146 | <1% | 249 | $32K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,629 | $32K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,441 | $31K |
| X0616 | <1% | 150 | $31K | |
| 20610 | <1% | 201 | $31K | |
| 70486 | <1% | 554 | $31K | |
| 72110 | <1% | 1,785 | $31K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,628 | $31K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 566 | $30K |
| 88185 | <1% | 197 | $30K | |
| 85730 | <1% | 6,987 | $30K | |
| 96158 | <1% | 766 | $30K | |
| 96376 | <1% | 1,517 | $29K | |
| 77334 | <1% | 591 | $29K | |
| 72158 | <1% | 174 | $29K | |
| 86480 | <1% | 449 | $29K | |
| 80076 | <1% | 5,081 | $29K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,118 | $29K |
| 73610 | <1% | 1,858 | $27K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,248 | $27K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,702 | $27K |
| 83605 | <1% | 5,146 | $26K | |
| 93970 | <1% | 391 | $26K | |
| 83880 | <1% | 1,313 | $26K | |
| 83690 | <1% | 8,575 | $26K | |
| 93971 | <1% | 555 | $26K | |
| 88341 | <1% | 535 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,202 | $24K |
| 86833 | <1% | 412 | $24K | |
| 86235 | <1% | 384 | $23K | |
| 84703 | <1% | 3,599 | $22K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,734 | $22K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,149 | $21K |
| 73030 | <1% | 1,719 | $20K | |
| 73630 | <1% | 2,289 | $20K | |
| 95886 | <1% | 656 | $19K | |
| 84100 | <1% | 6,422 | $19K | |
| 72156 | <1% | 113 | $19K | |
| 95913 | <1% | 264 | $19K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 127 | $18K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 921 | $18K |
| 72082 | <1% | 727 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 561 | $18K |
| 73130 | <1% | 1,802 | $17K | |
| 82728 | <1% | 2,146 | $17K | |
| 73502 | <1% | 1,251 | $17K | |
| 72100 | <1% | 980 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,815 | $17K |
| J1815 | Injection, insulin, per 5 units | <1% | 4,381 | $17K |
| 72131 | <1% | 323 | $16K | |
| 96159 | <1% | 486 | $16K | |
| 72050 | <1% | 755 | $16K | |
| 73562 | <1% | 1,261 | $16K | |
| 86003 | <1% | 181 | $16K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 521 | $16K |
| 82565 | <1% | 5,190 | $16K | |
| 94010 | <1% | 1,642 | $16K | |
| 43235 | <1% | 260 | $16K | |
| 88342 | <1% | 825 | $16K | |
| 90715 | <1% | 2,319 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,702 | $15K |
| 82607 | <1% | 1,910 | $15K | |
| 87040 | <1% | 1,534 | $15K | |
| 73110 | <1% | 1,577 | $15K | |
| 88112 | <1% | 566 | $15K | |
| 76770 | <1% | 438 | $15K | |
| 81003 | <1% | 7,417 | $15K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 181 | $14K |
| 86702 | <1% | 1,217 | $14K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 296 | $14K |
| 94729 | <1% | 649 | $14K | |
| 73564 | <1% | 889 | $14K | |
| 77300 | <1% | 258 | $14K | |
| 17110 | <1% | 295 | $14K | |
| 82784 | <1% | 619 | $14K | |
| 86780 | <1% | 1,021 | $14K | |
| 77336 | <1% | 454 | $14K | |
| 84134 | <1% | 937 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,978 | $13K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,446 | $13K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 28,279 | $13K |
| 83970 | <1% | 400 | $13K | |
| 93017 | <1% | 472 | $13K | |
| 86850 | <1% | 2,525 | $13K | |
| 73718 | <1% | 57 | $13K | |
| 97161 | <1% | 736 | $12K | |
| 73560 | <1% | 1,059 | $12K | |
| 71271 | <1% | 153 | $12K | |
| 87497 | <1% | 410 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 28 | $11K |
| 86701 | <1% | 1,217 | $11K | |
| 82977 | <1% | 1,644 | $11K | |
| 99201 | <1% | 269 | $11K | |
| 85027 | <1% | 3,228 | $11K | |
| 73700 | <1% | 219 | $11K | |
| 80197 | <1% | 1,292 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 355 | $10K |
| 73590 | <1% | 858 | $10K | |
| 82105 | <1% | 785 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,450 | $10K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 762 | $10K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 96 | $10K |
| 86803 | <1% | 665 | $10K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 657 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 35,327 | $10K |
| 81025 | <1% | 3,806 | $10K | |
| 82803 | <1% | 605 | $10K | |
| 87390 | <1% | 1,205 | $9K | |
| 82962 | <1% | 7,325 | $9K | |
| 86923 | <1% | 252 | $9K | |
| 72157 | <1% | 58 | $9K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,245 | $9K |
| 87081 | <1% | 2,400 | $9K | |
| 83540 | <1% | 1,553 | $8K | |
| 97162 | <1% | 486 | $8K | |
| 84702 | <1% | 704 | $8K | |
| 72128 | <1% | 154 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 309 | $8K |
| 78264 | <1% | 91 | $8K | |
| 81001 | <1% | 3,746 | $8K | |
| 87340 | <1% | 731 | $8K | |
| 84439 | <1% | 1,266 | $8K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 219 | $8K |
| 76830 | Ultrasound, transvaginal | <1% | 238 | $8K |
| 36430 | <1% | 184 | $7K | |
| 73552 | <1% | 611 | $7K | |
| 85379 | <1% | 1,059 | $7K | |
| 86706 | <1% | 706 | $7K | |
| 84153 | <1% | 325 | $7K | |
| 95911 | <1% | 121 | $7K | |
| 72040 | <1% | 535 | $7K | |
| 86361 | <1% | 274 | $7K | |
| 87070 | <1% | 1,540 | $7K | |
| 94726 | <1% | 311 | $7K | |
| 86901 | <1% | 2,534 | $6K | |
| 86900 | <1% | 2,527 | $6K | |
| 93320 | <1% | 174 | $6K | |
| 92250 | <1% | 193 | $6K | |
| 11102 | <1% | 144 | $6K | |
| 82550 | <1% | 1,360 | $6K | |
| 82746 | <1% | 942 | $6K | |
| 70487 | <1% | 118 | $6K | |
| 80329 | <1% | 619 | $6K | |
| 86038 | <1% | 485 | $6K | |
| 82043 | <1% | 964 | $6K | |
| 77002 | <1% | 281 | $6K | |
| 86704 | <1% | 478 | $5K | |
| 87077 | <1% | 1,031 | $5K | |
| P9021 | Red blood cells, each unit | <1% | 104 | $5K |
| J8501 | Aprepitant, oral, 5 mg | <1% | 395 | $5K |
| 94060 | <1% | 624 | $5K | |
| 74018 | <1% | 632 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 162 | $5K |
| 90682 | <1% | 543 | $5K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 25 | $5K |
| 83550 | <1% | 1,509 | $5K | |
| 86140 | <1% | 2,505 | $5K | |
| 93226 | <1% | 162 | $5K | |
| 72070 | <1% | 294 | $5K | |
| 80047 | <1% | 689 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 186 | $5K |
| 83615 | <1% | 996 | $4K | |
| 80051 | <1% | 1,258 | $4K | |
| 95885 | <1% | 200 | $4K | |
| 73140 | <1% | 560 | $4K | |
| 84520 | <1% | 1,514 | $4K | |
| 86708 | <1% | 313 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $4K |
| 88313 | <1% | 258 | $4K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,231 | $4K |
| 88184 | <1% | 200 | $4K | |
| 73070 | <1% | 447 | $4K | |
| 75574 | <1% | 26 | $4K | |
| 76870 | <1% | 119 | $4K | |
| 74220 | <1% | 276 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 45 | $4K |
| 86831 | <1% | 70 | $4K | |
| 73222 | <1% | 13 | $4K | |
| 83021 | <1% | 275 | $4K | |
| 90674 | <1% | 1,104 | $4K | |
| 86160 | <1% | 248 | $4K | |
| 87905 | <1% | 391 | $4K | |
| 73090 | <1% | 399 | $4K | |
| 84165 | <1% | 313 | $4K | |
| 78227 | <1% | 12 | $4K | |
| 93350 | <1% | 92 | $3K | |
| 87205 | <1% | 1,367 | $3K | |
| 87186 | <1% | 726 | $3K | |
| 86592 | <1% | 1,016 | $3K | |
| 97165 | <1% | 283 | $3K | |
| 92540 | <1% | 366 | $3K | |
| 76942 | <1% | 529 | $3K | |
| 82570 | <1% | 738 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 142 | $3K |
| 85014 | <1% | 1,765 | $3K | |
| 85652 | <1% | 1,524 | $3K | |
| 87808 | <1% | 386 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,282 | $3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 100 | $3K |
| 46600 | <1% | 192 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 46 | $3K |
| 73060 | <1% | 358 | $3K | |
| 86618 | <1% | 190 | $3K | |
| 84403 | <1% | 117 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 321 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,029 | $3K |
| 85018 | <1% | 1,376 | $3K | |
| 80069 | <1% | 539 | $3K | |
| 72190 | <1% | 149 | $3K | |
| 82947 | <1% | 1,159 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 9,051 | $3K |
| 73200 | <1% | 56 | $3K | |
| 86902 | <1% | 93 | $3K | |
| 93880 | <1% | 29 | $3K | |
| C1769 | Guide wire | <1% | 446 | $3K |
| 96156 | <1% | 60 | $3K | |
| 95819 | <1% | 260 | $2K | |
| 78306 | <1% | 52 | $2K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,564 | $2K |
| 72195 | <1% | 14 | $2K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $2K |
| 85045 | <1% | 824 | $2K | |
| 82785 | <1% | 169 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,492 | $2K |
| 90732 | <1% | 116 | $2K | |
| 73080 | <1% | 263 | $2K | |
| 84550 | <1% | 611 | $2K | |
| 84132 | <1% | 569 | $2K | |
| 74160 | <1% | 43 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 4,212 | $2K |
| 92546 | <1% | 381 | $2K | |
| 95708 | <1% | 22 | $2K | |
| 64483 | <1% | 30 | $2K | |
| 87517 | <1% | 77 | $2K | |
| 82533 | <1% | 195 | $2K | |
| 86800 | <1% | 135 | $2K | |
| 95912 | <1% | 27 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 54 | $2K |
| 93923 | <1% | 43 | $2K | |
| 93225 | <1% | 163 | $2K | |
| 88312 | <1% | 106 | $2K | |
| 84402 | <1% | 73 | $2K | |
| 84146 | <1% | 84 | $2K | |
| 81002 | <1% | 736 | $2K | |
| 86256 | <1% | 146 | $2K | |
| 73501 | <1% | 191 | $2K | |
| 80321 | <1% | 147 | $2K | |
| 97166 | <1% | 162 | $2K | |
| 83001 | <1% | 92 | $2K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 218 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 679 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 861 | $2K |
| 87102 | <1% | 377 | $2K | |
| 88237 | <1% | 13 | $2K | |
| 72170 | <1% | 238 | $2K | |
| 73000 | <1% | 149 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 498 | $2K |
| 85651 | <1% | 823 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,739 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,001 | $1K |
| 84295 | <1% | 360 | $1K | |
| 86334 | <1% | 76 | $1K | |
| 93271 | <1% | 42 | $1K | |
| 86644 | <1% | 80 | $1K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 24 | $1K |
| 85240 | <1% | 93 | $1K | |
| 70547 | <1% | 12 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 70 | $1K |
| 80177 | <1% | 158 | $1K | |
| 82310 | <1% | 380 | $1K | |
| 88307 | <1% | 408 | $1K | |
| 86431 | <1% | 219 | $1K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,615 | $1K |
| 87075 | <1% | 283 | $1K | |
| 92537 | <1% | 254 | $1K | |
| 89051 | <1% | 413 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,529 | $1K |
| 77412 | <1% | 43 | $1K | |
| 84432 | <1% | 60 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,122 | $1K |
| 82040 | <1% | 547 | $1K | |
| 86580 | <1% | 249 | $1K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,978 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,764 | $1K |
| 88264 | <1% | 13 | $1K | |
| 82810 | <1% | 108 | $1K | |
| 82330 | <1% | 262 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,712 | $1K |
| 82103 | <1% | 72 | $1K | |
| 92547 | <1% | 411 | $1K | |
| 84460 | <1% | 280 | $1K | |
| C9399 | Unclassified drugs or biologicals | <1% | 269 | $1K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,990 | $1K |
| 82104 | <1% | 69 | $1K | |
| 82150 | <1% | 325 | $1K | |
| 84156 | <1% | 426 | $1K | |
| 72114 | <1% | 76 | $1K | |
| 29826 | <1% | 12 | $1K | |
| 74019 | <1% | 96 | $980.74 | |
| 86200 | <1% | 83 | $968.87 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 341 | $966.82 |
| 86713 | <1% | 76 | $965.62 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 209 | $918.16 |
| 90750 | <1% | 85 | $859.88 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 213 | $841.98 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 893 | $838.93 |
| 76937 | <1% | 287 | $832.18 | |
| 82248 | <1% | 139 | $825.12 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 606 | $818.93 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,233 | $806.94 |
| 94618 | <1% | 87 | $806.21 | |
| 86787 | <1% | 50 | $786.65 | |
| 73620 | <1% | 120 | $782.49 | |
| 85049 | <1% | 489 | $780.22 | |
| 86617 | <1% | 28 | $779.60 | |
| 87799 | <1% | 101 | $750.23 | |
| 84450 | <1% | 177 | $749.49 | |
| 73521 | <1% | 75 | $748.72 | |
| 94760 | <1% | 1,726 | $747.69 | |
| 80164 | <1% | 65 | $744.05 | |
| 77012 | <1% | 30 | $718.46 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28 | $709.83 |
| 92611 | <1% | 29 | $699.55 | |
| 70480 | <1% | 12 | $698.32 | |
| 86255 | <1% | 31 | $692.68 | |
| 74230 | <1% | 39 | $691.04 | |
| 83010 | <1% | 103 | $688.32 | |
| 86376 | <1% | 107 | $672.98 | |
| 85576 | <1% | 61 | $644.61 | |
| 82164 | <1% | 45 | $638.63 | |
| 82390 | <1% | 63 | $630.81 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 145 | $629.16 |
| 95910 | <1% | 12 | $624.72 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,193 | $623.57 |
| 96136 | <1% | 128 | $623.00 | |
| 82140 | <1% | 249 | $615.84 | |
| 84425 | <1% | 164 | $612.34 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 50 | $605.42 |
| 86695 | <1% | 38 | $600.35 | |
| 91322 | <1% | 14 | $585.92 | |
| 86317 | <1% | 30 | $571.70 | |
| 84446 | <1% | 60 | $567.31 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,051 | $559.08 |
| 84157 | <1% | 228 | $519.55 | |
| 84590 | <1% | 45 | $515.11 | |
| 86664 | <1% | 30 | $508.76 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,663 | $508.60 |
| 87116 | <1% | 151 | $501.76 | |
| 82375 | <1% | 140 | $501.24 | |
| 99152 | <1% | 155 | $493.80 | |
| 84155 | <1% | 175 | $481.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,686 | $462.27 |
| 86777 | <1% | 26 | $458.74 | |
| 80074 | <1% | 13 | $458.36 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 396 | $440.27 |
| 86663 | <1% | 30 | $440.17 | |
| 86645 | <1% | 15 | $427.77 | |
| 72020 | <1% | 46 | $424.64 | |
| 86021 | <1% | 115 | $423.77 | |
| 84075 | <1% | 104 | $410.68 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 400 | $407.30 |
| 93270 | <1% | 39 | $403.87 | |
| 86665 | <1% | 30 | $401.28 | |
| 84480 | <1% | 73 | $398.47 | |
| 87015 | <1% | 109 | $397.05 | |
| 85660 | <1% | 101 | $376.72 | |
| 73120 | <1% | 46 | $373.72 | |
| 84436 | <1% | 54 | $364.61 | |
| 0001A | <1% | 101 | $360.00 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 127 | $345.51 |
| 87184 | <1% | 59 | $325.54 | |
| 73600 | <1% | 57 | $322.02 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,170 | $311.96 |
| 86696 | <1% | 13 | $311.88 | |
| 82247 | <1% | 108 | $293.30 | |
| 97542 | <1% | 16 | $285.37 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,628 | $278.15 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 745 | $276.40 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,568 | $274.91 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 424 | $272.32 |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 12 | $264.37 |
| 97163 | <1% | 14 | $263.82 | |
| 73100 | <1% | 29 | $254.25 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,515 | $242.31 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 466 | $241.31 |
| 70250 | <1% | 16 | $239.03 | |
| 95816 | <1% | 46 | $238.71 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,136 | $235.22 |
| 97167 | <1% | 12 | $232.70 | |
| 76882 | <1% | 39 | $225.70 | |
| 82805 | <1% | 12 | $222.68 | |
| 93041 | <1% | 96 | $221.27 | |
| 80202 | <1% | 26 | $217.14 | |
| 84300 | <1% | 56 | $210.91 | |
| 87206 | <1% | 156 | $206.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 60 | $192.34 |
| 88304 | <1% | 232 | $184.12 | |
| 36600 | <1% | 26 | $176.76 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,550 | $176.06 |
| 87430 | <1% | 39 | $169.66 | |
| 84630 | <1% | 14 | $161.21 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 27 | $160.92 |
| 87181 | <1% | 24 | $159.50 | |
| 89050 | <1% | 236 | $158.40 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 248 | $157.81 |
| 94761 | <1% | 108 | $154.82 | |
| 80178 | <1% | 30 | $149.60 | |
| 85097 | <1% | 13 | $147.84 | |
| 86705 | <1% | 12 | $144.00 | |
| 82378 | <1% | 12 | $141.30 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 357 | $138.77 |
| 86769 | <1% | 14 | $136.83 | |
| 86141 | <1% | 13 | $127.17 | |
| 71101 | <1% | 13 | $119.02 | |
| 86308 | <1% | 29 | $118.76 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 723 | $115.87 |
| 82652 | <1% | 12 | $112.94 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 16 | $109.87 |
| 82525 | <1% | 14 | $106.76 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 137 | $99.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 534 | $89.68 |
| 83930 | <1% | 47 | $88.80 | |
| 80158 | <1% | 15 | $87.15 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,111 | $78.91 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 114 | $68.29 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 105 | $64.72 |
| 85732 | <1% | 15 | $64.66 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 14 | $57.89 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 4,295 | $51.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,787 | $46.90 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 45 | $46.22 |
| 0002A | <1% | 87 | $40.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,127 | $39.14 |
| 88300 | <1% | 115 | $37.50 | |
| 85048 | <1% | 15 | $34.48 | |
| 77003 | <1% | 14 | $31.01 | |
| 83935 | <1% | 14 | $29.40 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 118 | $26.40 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 46 | $20.16 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 115 | $19.26 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 108 | $15.92 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 49 | $14.16 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 40 | $13.60 |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 52 | $10.23 |
| 85041 | <1% | 18 | $7.64 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 89 | $6.24 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 61 | $5.50 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 88 | $3.60 |
| 91300 | <1% | 77 | $0.76 | |
| 90677 | 0% | 374 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 2,546 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 12 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 58 | $0.00 |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 0% | 35 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 53 | $0.00 |
| 90673 | 0% | 237 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 112 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 15 | $0.00 |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 0% | 26 | $0.00 |
| 90480 | 0% | 15 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 13 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 118 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 38 | $0.00 |
| 90611 | 0% | 28 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 640 | $0.00 |
| 88173 | 0% | 27 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 98 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 182 | $0.00 |
| 90661 | 0% | 189 | $0.00 | |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 97 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 39 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 15 | $0.00 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 0% | 34 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 38 | $0.00 |
| 90734 | 0% | 13 | $0.00 | |
| S0030 | Injection, metronidazole, 500 mg | 0% | 69 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEINER, JARED (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Washington | Washington, PA | $11.22M |
| UPMC Greene | Waynesburg, PA | $2.67M |
| UPMC Presbyterian Shadyside | Pittsburgh, PA | $131K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.